# v4.22\n\n## Related releases\n\n## Data changes\n

### Gene

```
ADARB2 Summary Updated
ADARB2 Background Updated
BUB1B Background Updated
BUB1B Summary Updated
CCN6 Background Updated
CCN6 Summary Updated
CDKN1C Summary Updated
CDKN1C Background Updated
EGR2 Background Updated
EGR2 Summary Updated
```

### Alteration

```
ADARB2 Amplification, Mutation Effect, Description Updated
ADARB2 Amplification, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
ADARB2 Amplification, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
ADARB2 Amplification Added
BRCA2 R2318Q, Mutation Effect, Description Updated
CCN6 Deletion, Mutation Effect, Description Updated
CCN6 Deletion, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
CCN6 Deletion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
CCN6 Deletion Added
CCN6 Amplification, Mutation Effect, Description Updated
CCN6 Amplification, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
CCN6 Amplification, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
CCN6 Amplification Added
CCN6 Truncating Mutation, Mutation Effect, Description Updated
CCN6 Truncating Mutation, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
CCN6 Truncating Mutation, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
CCN6 Truncating Mutation Added
CDKN1C Deletion, Mutation Effect, Description Updated
CDKN1C Deletion, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
CDKN1C Deletion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
CDKN1C Deletion Added
CDKN1C Truncating Mutations, Mutation Effect, Description Updated
CDKN1C Truncating Mutations, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
CDKN1C Truncating Mutations, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
CDKN1C Truncating Mutations Added
EGFR G724S, Mutation Effect, Description Updated
EGR2 Deletion, Mutation Effect, Description Updated
EGR2 Deletion, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
EGR2 Deletion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
EGR2 Deletion Added
EZH2 K515R, Mutation Effect, Description Updated
EZH2 K515R, Mutation Effect, Effect Updated
	 New: Inconclusive
	 Old: Likely Neutral
EZH2 K515R, Mutation Effect, Oncogenic Updated
	 New: Inconclusive
	 Old: Likely Neutral
FGFR2 FGFR2-TACC2 Fusion, Mutation Effect, Description Updated
FGFR2 deltaE18 [Exon 18 deletion], Mutation Effect, Description Updated
FGFR2 FGFR2-INA Fusion, Mutation Effect, Description Updated
FGFR2 FGFR2-USP33 Fusion, Mutation Effect, Description Updated
KIT Q556_K558del (Exon 11), Mutation Effect, Description Updated
RET Fusions, Mutation Effect, Description Updated
RET V804M, Mutation Effect, Description Updated
RET D898_E901del, Mutation Effect, Description Updated
ROS1 G2032R, Mutation Effect, Description Updated
ROS1 L2086F, Mutation Effect, Description Updated
ROS1 L2086F, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
ROS1 L2086F, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
ROS1 L2086F Added
ROS1 CCDC6-ROS1 Fusion, Mutation Effect, Description Updated
ROS1 L2086F, Mutation Effect, Effect Updated
	 New:
	 Old: Likely Gain-of-function
ROS1 L2086F, Mutation Effect, Oncogenic Updated
	 New: Resistance
	 Old: Likely
SMARCA4 Oncogenic Mutations Added
```

### Evidence

```
ADARB2 Gene Type, Oncogene Updated
ALK Fusions, Non-Small Cell Lung Cancer, NVL-655, Description Updated
ALK Fusions, Non-Small Cell Lung Cancer, NVL-655, FDA Level Updated
	 New: Fda3
	 Old: no
ALK Fusions, Non-Small Cell Lung Cancer, NVL-655, Level Updated
	 New: 3A
	 Old:
ALK Fusions, Non-Small Cell Lung Cancer, NVL-655, Propagation to Other Liquid Tumor Types Updated
ALK Fusions, Non-Small Cell Lung Cancer, NVL-655, Propagation to Other Solid Tumor Types Updated
ALK Fusions, Non-Small Cell Lung Cancer, NVL-655 3A Added
ALK G1202R, Non-Small Cell Lung Cancer, NVL-655, Description Updated
ALK G1202R, Non-Small Cell Lung Cancer, NVL-655, FDA Level Updated
	 New: Fda3
	 Old: no
ALK G1202R, Non-Small Cell Lung Cancer, NVL-655, Level Updated
	 New: 3A
	 Old:
ALK G1202R, Non-Small Cell Lung Cancer, NVL-655, Propagation to Other Liquid Tumor Types Updated
ALK G1202R, Non-Small Cell Lung Cancer, NVL-655, Propagation to Other Solid Tumor Types Updated
ALK G1202R, Non-Small Cell Lung Cancer, NVL-655 3A Added
ALK G1202R, Other Tumor Types, Summary Updated
ALK I1171N, L1196M, G1202R, Non-Small Cell Lung Cancer, Summary Updated
ALK G1123S, C1156Y, F1174C, L, V, D1203N, Non-Small Cell Lung Cancer, Summary Updated
ALK T1151dup, L1152R, I1171S, I1171T, L1196Q, S1206Y, E1210K, F1245C, G1269A, Non-Small Cell Lung Cancer, Summary Updated
ALK C1156Y, Non-Small Cell Lung Cancer, Summary Updated
ALK G1269A, Non-Small Cell Lung Cancer, Summary Updated
ALK I1171N, Non-Small Cell Lung Cancer, Summary Updated
ALK Oncogenic Mutations, Non-Small Cell Lung Cancer, Summary Updated
ALK Oncogenic Mutations, Other Tumor Types, Summary Updated
BRAF V600E, Colorectal Cancer, Encorafenib + Cetuximab, Additional Information Updated
BRCA1 Oncogenic Mutations, Prostate Cancer, Prostate Cancer, NOS, Olaparib + Abiraterone + Prednisone Name Changed
	 New: 578af76a-2e8a-463a-b7bd-0494c91ad2a1 + ba9b5a53-2261-4997-b4c1-ed87a5896e43 + 992573c5-802e-4748-8ae4-5aa3cf0834ff
	 Old: 578af76a-2e8a-463a-b7bd-0494c91ad2a1 + ba9b5a53-2261-4997-b4c1-ed87a5896e43 + 992573c5-802e-4748-8ae4-5aa3cf0834ff, 578af76a-2e8a-463a-b7bd-0494c91ad2a1 + ba9b5a53-2261-4997-b4c1-ed87a5896e43 + 2e8ce490-86c2-45a4-a6e4-db5e5314981c
BRCA2 Oncogenic Mutations, Prostate Cancer, Prostate Cancer, NOS, Olaparib + Abiraterone + Prednisone Name Changed
	 New: 578af76a-2e8a-463a-b7bd-0494c91ad2a1 + ba9b5a53-2261-4997-b4c1-ed87a5896e43 + 992573c5-802e-4748-8ae4-5aa3cf0834ff
	 Old: 578af76a-2e8a-463a-b7bd-0494c91ad2a1 + ba9b5a53-2261-4997-b4c1-ed87a5896e43 + 992573c5-802e-4748-8ae4-5aa3cf0834ff, 578af76a-2e8a-463a-b7bd-0494c91ad2a1 + ba9b5a53-2261-4997-b4c1-ed87a5896e43 + 2e8ce490-86c2-45a4-a6e4-db5e5314981c
BUB1B Gene Type, Oncogene Updated
CCN6 Gene Type, Oncogene Updated
CCN6 Gene Type, Tumor Suppressor Updated
CDKN1C Gene Type, Tumor Suppressor Updated
EGFR T790M, Non-Small Cell Lung Cancer, Osimertinib, Description Updated
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Osimertinib + Chemotherapy, Description Updated
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Osimertinib, Description Updated
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Osimertinib, Additional Information Updated
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy, Description Updated
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy, Level Updated
	 New: 1
	 Old: 2
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy, Propagation to Other Liquid Tumor Types Updated
EGR2 Gene Type, Tumor Suppressor Updated
FGFR1 Oncogenic Mutations, All Solid Tumors, Erdafitinib, Fexagratinib, Description Updated
FGFR1 Fusions, Myeloid, Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA, PDGFRB or FGFR1 or with PCM1-JAK2, Summary Updated
FGFR2 Oncogenic Mutations, All Solid Tumors {excluding Bladder Cancer}, Summary Updated
FGFR2 Oncogenic Mutations, All Solid Tumors {excluding Bladder Cancer}, Erdafitinib, Fexagratinib, Description Updated
FGFR2 Oncogenic Mutations, Cholangiocarcinoma, Summary Updated
FGFR2 Oncogenic Mutations, Cholangiocarcinoma, Lirafugratinib, Description Updated
FGFR2 Oncogenic Mutations, All Solid Tumors {excluding Cholangiocarcinoma, Bladder Cancer}, Summary Updated
FGFR2 Oncogenic Mutations, All Solid Tumors {excluding Cholangiocarcinoma, Bladder Cancer}, Lirafugratinib, Description Updated
FGFR2 Fusions, Other Solid Tumor Types {excluding Bladder Cancer}, Summary Updated
FGFR2 Fusions, Cholangiocarcinoma, Lirafugratinib, Description Updated
FGFR2 Oncogenic Mutations {excluding Fusions}, Bladder Cancer, Summary Updated
FGFR2 Oncogenic Mutations {excluding Fusions}, Bladder Cancer, Erdafitinib, Fexagratinib, Description Updated
FGFR2 Oncogenic Mutations {excluding Fusions}, Bladder Cancer, Lirafugratinib, Description Updated
FGFR2 Amplification, All Solid Tumors, Summary Updated
FGFR2 Amplification, All Solid Tumors, Lirafugratinib, Description Updated
FGFR3 FGFR3-TACC3 Fusion, FGFR3-BAIAP2L1 Fusion, Other Solid Tumor Types, Summary Updated
FGFR3 Oncogenic Mutations, All Solid Tumors, Summary Updated
FGFR3 Oncogenic Mutations, All Solid Tumors, Erdafitinib, Fexagratinib, Description Updated
KRAS G12D, All Solid Tumors, ASP3082, Description Updated
KRAS G12D, Non-Small Cell Lung Cancer, Summary Updated
KRAS G12D, Non-Small Cell Lung Cancer, ASP3082, Description Updated
KRAS G12D, Non-Small Cell Lung Cancer, ASP3082, FDA Level Updated
	 New: Fda3
	 Old: no
KRAS G12D, Non-Small Cell Lung Cancer, ASP3082, Level Updated
	 New: 3A
	 Old:
KRAS G12D, Non-Small Cell Lung Cancer, ASP3082, Propagation to Other Liquid Tumor Types Updated
KRAS G12D, Pancreatic Adenocarcinoma, ASP3082, Description Updated
KRAS G12D, Pancreatic Adenocarcinoma, Summary Updated
KRAS G12D, Pancreatic Adenocarcinoma, ASP3082, FDA Level Updated
	 New: Fda3
	 Old: no
KRAS G12D, Pancreatic Adenocarcinoma, ASP3082, Level Updated
	 New: 3A
	 Old:
KRAS G12D, Pancreatic Adenocarcinoma, ASP3082, Propagation to Other Liquid Tumor Types Updated
KRAS G12D, Non-Small Cell Lung Cancer, ASP3082, Propagation to Other Solid Tumor Types Updated
KRAS G12D, Non-Small Cell Lung Cancer Added
KRAS G12D, Non-Small Cell Lung Cancer, ASP3082 3A Added
KRAS G12D, Pancreatic Adenocarcinoma, ASP3082, Propagation to Other Solid Tumor Types Updated
KRAS G12D, Pancreatic Adenocarcinoma Added
KRAS G12D, Pancreatic Adenocarcinoma, ASP3082 3A Added
KRAS G12D, Colorectal Cancer, Summary Updated
KRAS Oncogenic Mutations, Colorectal Cancer, Summary Updated
KRAS Oncogenic Mutations, Appendiceal Cancer Name Changed
	 New: Appendiceal Cancer
	 Old: Appendiceal Adenocarcinoma
KRAS Oncogenic Mutations, Histiocytosis, Summary Updated
KRAS G12A, D, R, S, V, Pancreatic Adenocarcinoma, Summary Updated
KRAS Oncogenic Mutations, Non-Small Cell Lung Cancer Deleted
KRAS G12A, D, R, S, V, Non-Small Cell Lung Cancer, Summary Updated
KRAS G12A, D, R, S, V, All Solid Tumors, Summary Updated
KRAS G12A, D, R, S, V, Colorectal Cancer, Summary Updated
KRAS G12A, D, R, S, V, Colorectal Cancer Added
KRAS G12C, Non-Small Cell Lung Cancer, Summary Updated
KRAS G12C, Colorectal Cancer, Summary Updated
KRAS G12C, Esophagogastric Cancer, Anal Cancer, Gastrointestinal Neuroendocrine Tumors of the Esophagus, Stomach, Small Bowel Cancer, Tubular Adenoma of the Colon, Summary Updated
KRAS G12C, Pancreatic Adenocarcinoma, Summary Updated
KRAS G12C, Hepatobiliary Cancer, Summary Updated
KRAS G12C, Ampullary Cancer, Summary Updated
KRAS G12D, All Solid Tumors, Summary Updated
MTAP Deletion, All Solid Tumors, AMG 193, Description Updated
PIK3CA H1047R, Breast Cancer, Summary Updated
PIK3CA C420R, E542K, E545A, E545D, E545G, E545K, Q546E, Q546R, H1047L, H1047R, H1047Y, Breast Cancer, Summary Updated
PIK3CA C420R, E542K, E545A, E545D, E545G, E545K, Q546E, Q546R, H1047L, H1047R, H1047Y, Other Liquid Tumor Types, Summary Updated
PIK3CA R88Q, N345K, E545Q, Q546K, Q546P, M1043V, M1043I, G1049R, Breast Cancer, Summary Updated
PIK3CA R88Q, N345K, E545Q, Q546K, Q546P, M1043V, M1043I, G1049R, Other Liquid Tumor Types, Summary Updated
PIK3CA Oncogenic Mutations {excluding C420R; E542K; E545A; E545D; E545G; E545K; Q546E; Q546R; H1047L; H1047R; H1047Y; R88Q; N345K; E545Q; Q546K; Q546P; M1043V; M1043I; G1049R}, Breast Cancer, Summary Updated
PIK3CA Oncogenic Mutations {excluding C420R; E542K; E545A; E545D; E545G; E545K; Q546E; Q546R; H1047L; H1047R; H1047Y; R88Q; N345K; E545Q; Q546K; Q546P; M1043V; M1043I; G1049R}, Other Liquid Tumor Types, Summary Updated
PIK3CA Oncogenic Mutations, All Solid Tumors, Summary Updated
PIK3CA Oncogenic Mutations, Breast Cancer, Summary Updated
PIK3CA Oncogenic Mutations, Breast Cancer, Inavolisib + Palbociclib + Fulvestrant, Description Updated
PIK3CA Oncogenic Mutations, Breast Cancer, Inavolisib + Palbociclib + Fulvestrant, FDA Level Updated
	 New: Fda2
	 Old: Fda3
PIK3CA Oncogenic Mutations, Breast Cancer, Inavolisib + Palbociclib + Fulvestrant, Level Updated
	 New: 1
	 Old: 3A
PIK3CA Oncogenic Mutations, Breast Cancer, Inavolisib + Palbociclib + Fulvestrant, Propagation to Other Liquid Tumor Types Updated
PIK3CA Oncogenic Mutations, Breast Cancer, Inavolisib + Palbociclib + Fulvestrant, Additional Information Updated
PIK3CA Oncogenic Mutations {excluding C420R ; E542K ; E545A ; E545D ; E545G ; E545K ; Q546E ; Q546R ; H1047L ; H1047R ; H1047Y}, Breast Cancer, Summary Updated
PIK3CA Oncogenic Mutations {excluding C420R ; E542K ; E545A ; E545D ; E545G ; E545K ; Q546E ; Q546R ; H1047L ; H1047R ; H1047Y}, Other Liquid Tumor Types, Summary Updated
PIK3CA D350G, Melanoma Deleted
PIK3CA Oncogenic Mutations {excluding C420R; E542K; E545A; E545D; E545G; E545K; Q546E; Q546R; H1047L; H1047R; H1047Y; R88Q; N345K; E545Q; Q546K; Q546P; M1043V; M1043I; G1049R}, Other Liquid Tumor Types Deleted
PIK3CA Oncogenic Mutations {excluding C420R ; E542K ; E545A ; E545D ; E545G ; E545K ; Q546E ; Q546R ; H1047L ; H1047R ; H1047Y}, Other Liquid Tumor Types Deleted
PIK3CA Oncogenic Mutations, Colorectal Cancer, Summary Updated
RET Oncogenic Mutations, Medullary Thyroid Cancer, Pralsetinib, Description Updated
RET Oncogenic Mutations, Medullary Thyroid Cancer, Selpercatinib, Description Updated
ROS1 G2032R, Non-Small Cell Lung Cancer, Taletrectinib, Description Updated
ROS1 G2032R, Non-Small Cell Lung Cancer, Taletrectinib, FDA Level Updated
	 New: Fda3
	 Old: no
ROS1 G2032R, Non-Small Cell Lung Cancer, Taletrectinib, Level Updated
	 New: 3A
	 Old:
ROS1 G2032R, Non-Small Cell Lung Cancer, Taletrectinib, Propagation to Other Liquid Tumor Types Updated
ROS1 G2032R, Non-Small Cell Lung Cancer, Taletrectinib, Propagation to Other Solid Tumor Types Updated
ROS1 G2032R, Non-Small Cell Lung Cancer, Taletrectinib 3A Added
ROS1 G2032R, Non-Small Cell Lung Cancer, Summary Updated
ROS1 G2032R, Non-Small Cell Lung Cancer, Crizotinib, Description Updated
ROS1 G2032R, Non-Small Cell Lung Cancer, Crizotinib, FDA Level Updated
	 New: Fda3
	 Old: no
ROS1 G2032R, Non-Small Cell Lung Cancer, Crizotinib, Level Updated
	 New: R2
	 Old:
ROS1 G2032R, Non-Small Cell Lung Cancer, Crizotinib R2 Added
ROS1 G2032R, Non-Small Cell Lung Cancer, Lorlatinib, Description Updated
ROS1 G2032R, Non-Small Cell Lung Cancer, Lorlatinib, FDA Level Updated
	 New: Fda3
	 Old: no
ROS1 G2032R, Non-Small Cell Lung Cancer, Lorlatinib, Level Updated
	 New: R2
	 Old:
ROS1 G2032R, Non-Small Cell Lung Cancer Added
ROS1 G2032R, Non-Small Cell Lung Cancer, Lorlatinib R2 Added
ROS1 L2086F, Non-Small Cell Lung Cancer, Summary Updated
ROS1 L2086F, Non-Small Cell Lung Cancer, Cabozantinib, FDA Level Updated
	 New: Fda3
	 Old: no
ROS1 L2086F, Non-Small Cell Lung Cancer, Cabozantinib, Level Updated
	 New: 3A
	 Old:
ROS1 L2086F, Non-Small Cell Lung Cancer, Cabozantinib, Propagation to Other Liquid Tumor Types Updated
ROS1 L2086F, Non-Small Cell Lung Cancer, Cabozantinib, Propagation to Other Solid Tumor Types Updated
ROS1 L2086F, Non-Small Cell Lung Cancer, Lorlatinib, Description Updated
ROS1 L2086F, Non-Small Cell Lung Cancer, Lorlatinib, FDA Level Updated
	 New: Fda3
	 Old: no
ROS1 L2086F, Non-Small Cell Lung Cancer, Lorlatinib, Level Updated
	 New: R2
	 Old:
ROS1 L2086F, Non-Small Cell Lung Cancer, Lorlatinib R2 Added
ROS1 Fusions, Non-Small Cell Lung Cancer, Taletrectinib, Description Updated
ROS1 Fusions, Non-Small Cell Lung Cancer, Taletrectinib, FDA Level Updated
	 New: Fda3
	 Old: no
ROS1 L2086F, Non-Small Cell Lung Cancer, Repotrectinib, FDA Level Updated
	 New: Fda3
	 Old: no
ROS1 L2086F, Non-Small Cell Lung Cancer, Repotrectinib, Level Updated
	 New: R2
	 Old:
ROS1 Fusions, Non-Small Cell Lung Cancer, Taletrectinib, Level Updated
	 New: 3A
	 Old:
ROS1 Fusions, Non-Small Cell Lung Cancer, Taletrectinib, Propagation to Other Liquid Tumor Types Updated
ROS1 Fusions, Non-Small Cell Lung Cancer, Taletrectinib, Propagation to Other Solid Tumor Types Updated
ROS1 Fusions, Non-Small Cell Lung Cancer, Taletrectinib 3A Added
ROS1 L2086F, Non-Small Cell Lung Cancer, Cabozantinib, Description Updated
ROS1 L2086F, Non-Small Cell Lung Cancer, Cabozantinib 3A Added
ROS1 L2086F, Non-Small Cell Lung Cancer, Repotrectinib, Description Updated
ROS1 L2086F, Non-Small Cell Lung Cancer Added
ROS1 L2086F, Non-Small Cell Lung Cancer, Repotrectinib R2 Added
ROS1 L2086F, Other Tumor Types, Summary Updated
ROS1 L2086F, Other Tumor Types Added
ROS1 G2032R, Other Tumor Types, Summary Updated
ROS1 G2032R, Other Tumor Types Added
ROS1 Oncogenic Mutations, All Tumors, Summary Updated
SMARCA4 Oncogenic Mutations, Non-Small Cell Lung Cancer, Summary Updated
SMARCA4 Oncogenic Mutations, Non-Small Cell Lung Cancer, PRT3789, Description Updated
SMARCA4 Oncogenic Mutations, Non-Small Cell Lung Cancer, PRT3789, FDA Level Updated
	 New: Fda3
	 Old: no
SMARCA4 Oncogenic Mutations, Non-Small Cell Lung Cancer, PRT3789, Level Updated
	 New: 3A
	 Old:
SMARCA4 Oncogenic Mutations, Non-Small Cell Lung Cancer, PRT3789, Propagation to Other Liquid Tumor Types Updated
SMARCA4 Oncogenic Mutations, Non-Small Cell Lung Cancer, PRT3789, Propagation to Other Solid Tumor Types Updated
SMARCA4 Oncogenic Mutations, Non-Small Cell Lung Cancer Added
SMARCA4 Oncogenic Mutations, Non-Small Cell Lung Cancer, PRT3789 3A Added
SMARCA4 Oncogenic Mutations, Esophageal Adenocarcinoma, Summary Updated
SMARCA4 Oncogenic Mutations, Esophageal Adenocarcinoma, PRT3789, Description Updated
SMARCA4 Oncogenic Mutations, Esophageal Adenocarcinoma, PRT3789, FDA Level Updated
	 New: Fda3
	 Old: no
SMARCA4 Oncogenic Mutations, Esophageal Adenocarcinoma, PRT3789, Level Updated
	 New: 3A
	 Old:
SMARCA4 Oncogenic Mutations, Esophageal Adenocarcinoma, PRT3789, Propagation to Other Liquid Tumor Types Updated
SMARCA4 Oncogenic Mutations, Esophageal Adenocarcinoma, PRT3789, Propagation to Other Solid Tumor Types Updated
SMARCA4 Oncogenic Mutations, Esophageal Adenocarcinoma Added
SMARCA4 Oncogenic Mutations, Esophageal Adenocarcinoma, PRT3789 3A Added
SMARCA4 Oncogenic Mutations, Other Tumor Types, Summary Updated
SMARCA4 Oncogenic Mutations, Other Tumor Types Added
```
